Pulmonary complications of tumor necrosis factor-targeted therapy

Respiratory Medicine

Volumn 103, Issue 5, 2009, Pages 661-669

  Thavarajah, Krishna ^a   Wu, Peggy ^a   Rhew, Elisa J ^a   Yeldandi, Anjana K ^a   Kamp, David W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Drug induced lung disease; Pulmonary; Review; Side effects; TNF; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; AZITHROMYCIN; CEFTRIAXONE; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BRONCHIOLAR DI; BRONCHOSCOPY; BRONCHUS DISEASE; CROHN DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GRANULOMA; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG DISEASE; LUNG FIBROSIS; LUNG HEMORRHAGE; LUNG NODULE; LUNG TOXICITY; PNEUMONIA; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; ULCERATIVE COLITIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; COMMUNICABLE DISEASES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; LUNG DISEASES; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 62949224773     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.01.002     Document Type: Review

References (39)

1. Brightling C., Berry M., and Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. The Journal of Allergy and Clinical Immunology 121 1 (2008 Jan) 5-10 [quiz 1-2]
2. Klinkhoff A. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs 64 12 (2004) 1267-1283
3. Mouser J.F., and Hyams J.S. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clinical Therapeutics 21 6 (1999 Jun) 932-942 [discussion 1]
4. Scheinfeld N. Adalimumab (HUMIRA): a review. Journal of Drugs in Dermatology 2 4 (2003 Aug) 375-377
5. Goldenberg M.M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clinical Therapeutics 21 1 (1999 Jan) 75-87 discussion 1-2
6. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
7. Furst D.E., Wallis R., Broder M., and Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Seminars in Arthritis and Rheumatism 36 3 (2006 Dec) 159-167
8. Schluter D., and Deckert M. The divergent role of tumor necrosis factor receptors in infectious diseases. Microbes and Infection/Institut Pasteur 2 10 (2000 Aug) 1285-1292
9. Kruglov A.A., Kuchmiy A., Grivennikov S.I., Tumanov A.V., Kuprash D.V., and Nedospasov S.A. Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine & Growth Factor Reviews 19 3-4 (2008 Jun-Aug) 231-244
10. Ramos-Casals M., Brito-Zeron P., Soto M.J., Cuadrado M.J., and Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies. Best Practice & Research 22 5 (2008 Oct) 847-861
11. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. The New England Journal of Medicine 345 15 (2001 Oct 11) 1098-1104
12. Wood K.L., Hage C.A., Knox K.S., Kleiman M.B., Sannuti A., Day R.B., et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. American Journal of Respiratory and Critical Care Medicine 167 9 (2003 May 1) 1279-1282
13. Hage C.A., Wood K.L., Winer-Muram H.T., Wilson S.J., Sarosi G., and Knox K.S. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 124 6 (2003 Dec) 2395-2397
14. Imaizumi K., Sugishita M., Usui M., Kawabe T., Hashimoto N., and Hasegawa Y. Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis. Internal Medicine 45 10 (2006) 685-688
15. Kroesen S., Widmer A.F., Tyndall A., and Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford, England) 42 5 (2003 May) 617-621
16. Curtis J.R., Patkar N., Xie A., Martin C., Allison J.J., Saag M., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis and Rheumatism 56 4 (2007 Apr) 1125-1133
17. Peno-Green L., Lluberas G., Kingsley T., and Brantley S. Lung injury linked to etanercept therapy. Chest 122 5 (2002 Nov) 1858-1860
18. Phillips K., and Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis and Rheumatism 53 4 (2005 Aug 15) 618-620
19. Yousem S.A., and Dacic S. Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy. Modern Pathology 18 5 (2005 May) 651-655
20. Gonzalez-Lopez M.A., Blanco R., Gonzalez-Vela M.C., Fernandez-Llaca H., and Rodriguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis and Rheumatism 55 5 (2006 Oct 15) 817-820
21. Kudrin A., Chilvers E.R., Ginawi A., Hazleman B.L., Griffiths M.H., Thiru S., et al. Sarcoid-like granulomatous disease following etanercept treatment for RA. The Journal of Rheumatology 34 3 (2007 Mar) 648-649
22. Almodovar R., Izquierdo M., Zarco P., Javier Quiros F., Mazzucchelli R., and Steen B. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clinical and Experimental Rheumatology 25 1 (2007 Jan-Feb) 99-101
23. O'Shea F.D., Marras T.K., and Inman R.D. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis and Rheumatism 55 6 (2006 Dec 15) 978-981
24. Ziff M. The rheumatoid nodule. Arthritis and Rheumatism 33 6 (1990 Jun) 761-767
25. Baeten D., De Keyser F., Veys E.M., Theate Y., Houssiau F.A., and Durez P. Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules. Annals of the Rheumatic Diseases 63 5 (2004 May) 489-493
26. Cunnane G., Warnock M., Fye K.H., and Daikh D.I. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis and Rheumatism 47 4 (2002 Aug) 445-449
27. Kekow J., Welte T., Kellner U., and Pap T. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept. Arthritis and Rheumatism 46 3 (2002 Mar) 843-844
28. Hubscher O., Re R., and Iotti R. Pulmonary rheumatoid nodules in an etanercept-treated patient. Arthritis and Rheumatism 48 7 (2003 Jul) 2077-2078
29. van Ede A., den Broeder A., Wagenaar M., van Riel P., and Creemers M.C. Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis. The Journal of Rheumatology 34 7 (2007 Jul) 1590-1592
30. Ostor A.J., Chilvers E.R., Somerville M.F., Lim A.Y., Lane S.E., Crisp A.J., et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. The Journal of Rheumatology 33 3 (2006 Mar) 622-628
31. Rice A.J., Wells A.U., Bouros D., du Bois R.M., Hansell D.M., Polychronopoulos V., et al. Terminal diffuse alveolar damage in relation to interstitial pneumonias. An autopsy study. American Journal of Clinical Pathology 119 5 (2003 May) 709-714
32. Hagiwara K., Sato T., Takagi-Kobayashi S., Hasegawa S., Shigihara N., and Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. The Journal of Rheumatology 34 5 (2007 May) 1151-1154
33. Valesini G., Iannuccelli C., Marocchi E., Pascoli L., Scalzi V., and Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmunity Reviews 7 1 (2007 Nov) 35-41
34. Villeneuve E., St-Pierre A., and Haraoui B. Interstitial pneumonitis associated with infliximab therapy. The Journal of Rheumatology 33 6 (2006 Jun) 1189-1193
35. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scandinavian Jouranl of Rheumatology 33 4 (2004) 276-277
36. Courtney P.A., Alderdice J., and Whitehead E.M. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis and Rheumatism 49 4 (2003 Aug 15) 617 [author reply-8]
37. Kramer N., Chuzhin Y., Kaufman L.D., Ritter J.M., and Rosenstein E.D. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis and Rheumatism 47 6 (2002 Dec 15) 670-671
38. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86 4 (2007 Jul) 242-251
39. Diri E., Tello W., Ratnoff W.D., and Nugent K. Infliximab-induced SLE-like syndrome involving the lung and pleura. Lupus 16 9 (2007) 764-766